Dr
David
Millar

Trainee Patent Attorney

Glasgow Office

Electronics

Telephone. +44(0) 141 229 5800
Email. [email protected]

Experience

David graduated from the University of Glasgow in 2013 with a First Class Masters Degree (MEng) in Electronic and Electrical Engineering and was awarded the Lamb Master of Engineering Prize as the highest achieving MEng student in the final two years of study. During his time on the undergraduate course, he completed a 6-month placement at CERN, where he successfully designed a module which is responsible for monitoring the temperature of various electronic components on the large hadron collider.

From 2013-2017, David pursued a PhD in III-V compound semiconductor MOS technology, also at the University of Glasgow. During this time, he developed a world leading III-V junctionless MOSFET and presented his work at 4 international conferences.

Following his PhD, David was employed as a Postdoctoral Research Assistant working on antimonide MOSFETs as part of the INSIGHT collaboration: an EU funded project with partners from both academia and industry and a total budget of €4.25 million.

Qualifications

Trainee


MENG

Electrical and Electronics Engineering, University of Glasgow

PHD

Novel III-V MOS Technologies for Low Power Digital Logic Applications, University of Glasgow

Recognition

Lamb Prize - University of Glasgow

Awarded annually to the fifth year student in the MEng course in the Department of Electronics and Electrical Engineering, who has achieved the best overall performance in the final two years of the course.

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.